


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:23Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406828" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406828</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmjo</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406828</article-id><article-id pub-id-type="pmcid-ver">PMC12406828.1</article-id><article-id pub-id-type="pmcaid">12406828</article-id><article-id pub-id-type="pmcaiid">12406828</article-id><article-id pub-id-type="pmid">40897494</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2025-103676</article-id><article-id pub-id-type="publisher-id">bmjopen-2025-103676</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Protocol</subject></subj-group><subj-group subj-group-type="heading"><subject>Diagnostics</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1689</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>Diagnostic accuracy of nanopore sequencing for the rapid diagnosis of extrapulmonary tuberculosis: a protocol for a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8570-8013</contrib-id><name name-style="western"><surname>Yu</surname><given-names initials="G">Guocan</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/><xref rid="equal-contrib1" ref-type="author-notes">0</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="X">Xudong</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6066-3138</contrib-id><name name-style="western"><surname>Shen</surname><given-names initials="Y">Yanqin</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Ling</surname><given-names initials="Y">Yuyang</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="equal-contrib1" ref-type="author-notes">0</xref></contrib><aff id="aff1"><label>1</label><institution content-type="department">Tuberculosis Diagnosis and Treatment Center of Zhejiang Province</institution>, <institution>Hangzhou Red Cross Hospital</institution>, <addr-line content-type="city">Hangzhou</addr-line>, <addr-line content-type="state">Zhejiang</addr-line>, <country>China</country></aff><aff id="aff2"><label>2</label><institution>Hangzhou Red Cross Hospital</institution>, <addr-line content-type="city">Hangzhou</addr-line>, <addr-line content-type="state">Zhejiang</addr-line>, <country>China</country></aff><aff id="aff3"><label>3</label><institution content-type="department">The Second School of Clinical Medicine</institution>, <institution>Zhejiang Chinese Medical University</institution>, <addr-line content-type="city">Hangzhou</addr-line>, <addr-line content-type="state">Zhejiang</addr-line>, <country>China</country></aff></contrib-group><author-notes><fn><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn><fn fn-type="COI-statement" id="fn4"><p>None declared.</p></fn><corresp id="cor1">Dr Guocan Yu; <email xlink:href="dabaitwo@163.com">dabaitwo@163.com</email></corresp><fn fn-type="equal" id="equal-contrib1"><p>GY and YL contributed equally.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>9</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496158</issue-id><elocation-id>e103676</elocation-id><history><date date-type="received"><day>14</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bmjopen-15-9.pdf"/><self-uri xlink:title="pdf" xlink:href="bmjopen-15-9.pdf"/><abstract><title>Abstract</title><sec><title>Background</title><p>Extrapulmonary tuberculosis (EPTB) is a serious type of tuberculosis (TB) which can cause systemic clinical manifestations. Rapid diagnosis of EPTB for intervention is of great importance. Nanopore sequencing as a third-generation gene sequencing method is a new kind of rapid TB detection. Previous studies have shown that nanopore sequencing has higher diagnostic sensitivity and specificity for TB diagnosis compared with other diagnostic methods. The aim of this research is to develop a systematic review and meta-analysis protocol for assessing the accuracy of nanopore sequencing in diagnosing EPTB.</p></sec><sec><title>Methods and analysis</title><p>This protocol was conducted in strict adherence to the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols guidelines. The study protocol has been prospectively registered with the International Prospective Register of Systematic Reviews under the unique identifier CRD42024608415. We will search Chinese databases and English databases in June 2026. Chinese databases will include Wanfang database, China National Knowledge Infrastructure. English databases will include PubMed, EMBASE and the Cochrane Library. Adhering strictly to the reference standard outlined in this protocol, we will screen the literature. The Quality Assessment of Diagnostic Accuracy Studies will be used by us to assess the methodological quality of the included studies. The statistical tools used are Stata with midas commands and RevMan, and we will perform meta-analysis, generate forest plots and Summary Receiver Operating Characteristic curves. A p value of less than 0.05 will be considered statistically significant. If significant heterogeneity exists and there is a sufficient number of studies, we will investigate its source through subgroup analysis and meta-regression.</p></sec><sec><title>Ethics and dissemination</title><p>This investigation uses publicly accessible data repositories, exempting it from ethical review board approval requirements. On finalisation of the analysis, findings will be prepared for dissemination through submission to a reputable medical journal employing rigorous peer review processes. The study methodology adheres to established protocols for systematic review and meta-analysis.</p></sec><sec><title>PROSPERO registration number</title><p>CRD42024608415</p></sec></abstract><kwd-group><kwd>Tuberculosis</kwd><kwd>INTERNAL MEDICINE</kwd><kwd>GENERAL MEDICINE (see Internal Medicine)</kwd><kwd>Infectious diseases &amp; infestations</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Hangzhou Biomedicine and Health Industry Development Supporting Science and Technology Special Project</institution></institution-wrap></funding-source><award-id>2023WJC162</award-id><award-id>2023WJC312</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title></caption><list list-type="bullet" list-content="ul"><list-item><p>This protocol was developed in adherence to Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols reporting standards and prospectively registered on the International Prospective Register of Systematic Reviews international registry.</p></list-item><list-item><p>The review methodology incorporates evidence from both Chinese and English-language biomedical literature databases.</p></list-item><list-item><p>Implementation of validated quality assessment tools and standardised reporting parameters through methodological rigour and analytical robustness facilitates bias mitigation.</p></list-item><list-item><p>Substantial interstudy heterogeneity in outcome measurements may introduce potential instability in pooled outcome estimates.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> Tuberculosis (TB), a long-standing communicable illness attributable to the pathogenic infiltration of <italic toggle="yes">Mycobacterium tuberculosis</italic> (MTB), represents a clinically significant bacteriological condition. In 2023, an estimated 10.8&#8201;million people have contracted TB and 1.25&#8201;million have died as a result, posing a significant threat to human health.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> TB is divided into pulmonary and extrapulmonary TB (EPTB) based on the part of the lesion, and the lesion located outside the lung parenchyma is called EPTB, which can cause systemic clinical manifestations in addition to affecting the respiratory system,<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> and EPTB accounts for 15% of TB.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> Some of the EPTB diseases are of high criticality and present with severe clinical consequences,<xref rid="R4" ref-type="bibr"><sup>4 5</sup></xref> and delayed diagnosis can lead to progression of the disease, so rapid diagnosis for intervention is of great importance.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> Classical acid-fast bacilli (AFB) smear is the most commonly used method to diagnose TB; however, most EPTB specimens are pathogenically sparse, and therefore the positive detection rate of AFB smear is low<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> and they cannot be differentiated between MTB and non-tuberculosis mycobacteria.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> The conventional diagnostic gold standard for EPTB remains contingent on microbiological confirmation through definitive demonstration of MTB growth in clinical culture specimens. But the long culture time (approximately 2&#8211;7 weeks) and rapid progression of EPTB diseases make it easy to delay the disease.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> GeneXpert MTB/RIF (Rifampicin) is also one of the methods of rapid screening and has several advantages over traditional TB diagnostic methods, including minimal sample volume requirements and a turnaround time of less than 2&#8201;hours.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> However, the diagnostic sensitivity of GeneXpert MTB/RIF for AFB-negative, culture-positive samples still has room to improve.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> Nanopore sequencing, as a third-generation gene sequencing method with a turnaround time of 6&#8201;hours, is characterised by long read length, portability,<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> and previous studies have shown that nanopore sequencing has higher diagnostic sensitivity and specificity in diagnosing EPTB compared with the above diagnostic methods.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> Most of the current studies on nanopore sequencing for rapid diagnosis of EPTB are single-centre studies and lack evidence-based medical evidence.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> The purpose of this study is to create a protocol of the meta-analysis and systematic review about whether nanopore sequencing can improve the diagnosis of EPTB. We will also include an analysis comparing next-generation sequencing methods (eg, Illumina) versus nanopore sequencing. These technologies differ significantly in terms of read length, error rates, turnaround time and infrastructure requirements&#8212;all of which can impact diagnostic performance. For instance, next-generation sequencing provides highly accurate short reads but typically requires more complex laboratory setup and longer processing time. In contrast, nanopore sequencing offers portability and real-time sequencing, but with higher base-calling error rates. Comparing these platforms will provide valuable insights into their relative strengths and limitations for diagnosing EPTB, particularly given the diversity of clinical specimens and contexts. The EPTB covers a wide range of specimen types, and differences in specimen types, sequencing technology and data analysis pipelines may influence the diagnostic performance. All these factors will be explored in the study. We truly hope that clinical practitioners will better recognise the role of nanopore sequencing in the diagnosis of EPTB through this study.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Design and registration</title><p>This protocol was conducted in strict adherence to the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P) guidelines,<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> the PRISMA-P checklist is attached as <xref rid="SP1" ref-type="supplementary-material">online supplemental file S1</xref>. The study protocol has been prospectively registered with the International Prospective Register of Systematic Reviews under the unique identifier CRD42024608415. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Diagnostic Test Accuracy (PRISMA-DTA) statement,<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> we will report the complete study findings. This research was exempt from ethical approval as it is not required for articles categorised as systematic review and meta-analysis.</p></sec><sec id="s2-2"><title>Information sources</title><p>Separate searches will be carried out in both Chinese and English databases to identify studies pertaining to nanopore sequencing in the diagnosis of EPTB. The resources in China will include the China National Knowledge Infrastructure and Wanfang database, while the English-language databases will comprise PubMed, EMBASE and the Cochrane Library.</p></sec><sec id="s2-3"><title>Search strategy</title><p>Yuyang Ling and Xudong Xu, as two separate researchers, will finalise a topic-specific search strategy for each database and finalise it after discussion. They will work together to ensure an appropriate search approach. Searches will be done in English for the English databases and in Chinese for the Chinese databases in June 2026, with no time restrictions. An updated search will be conducted before completion of the review to reduce the likelihood of omitting studies that may be eligible for inclusion. The search strategies are included as <xref rid="SP2" ref-type="supplementary-material">online supplemental file S2</xref>.</p></sec><sec id="s2-4"><title>Eligibility criteria</title><sec id="s2-4-1"><title>Participants</title><p>There are no race, age or gender restrictions on the selection of patients with EPTB.</p></sec><sec id="s2-4-2"><title>Index tests</title><p>The index test will be nanopore sequencing.</p></sec><sec id="s2-4-3"><title>Comparator test</title><p>This study will not require a comparison experiment since this study focuses solely on assessing the diagnostic accuracy of nanopore sequencing for EPTB.</p></sec><sec id="s2-4-4"><title>Outcomes</title><p>Evaluation parameters will encompass diagnostic validity parameters including but not limited to specificity, sensitivity, negative predictive value (NPV), positive predictive value (PPV) and area under the receiver operating characteristic curve (AUC).</p></sec></sec><sec id="s2-5"><title>Study types</title><p>This study will include any research about diagnostic performance of nanopore sequencing for diagnosing EPTB.</p></sec><sec id="s2-6"><title>Reference standard</title><p>This protocol will have two reference standards, one for MTB culture and one for clinical diagnosis which is based on a comprehensive evaluation of several indicators. Clinical diagnosis includes clinical symptoms, tuberculin test, interferon-gamma release test and MTB antibody detection results, AFB smear, culture, molecular diagnostic results and the effectiveness of anti-TB treatment.</p></sec><sec id="s2-7"><title>Target conditions</title><p>This meta-analysis and systematic review will incorporate original research that has assessed nanopore sequencing for diagnosing EPTB and has established clear reference standards. We will consider studies that furnish data on true positives (TP), false positives (FP), false negatives (FN) and true negatives (TN), or where it is feasible to compute these metrics. In instances where the original research lacks adequate detail, we will reach out to the corresponding author for further information. Any studies that fail to report TP, FP, FN and TN values and cannot be calculated from reported information, or for which contacting the corresponding author has failed will be omitted from our analysis. Additionally, we will exclude reviews, case reports, conference abstracts lacking full texts and studies in languages other than Chinese or English.</p></sec><sec id="s2-8"><title>Literature screening and selection</title><p>Endnote (V.9.2) will be used by us to manage the literature collected from the various databases. We will screen the literature rigorously according to the inclusion and exclusion criteria outlined in this study. Relevant studies will be screened for relevance to the research project by two independent researchers (Yuyang Ling and Xudong Xu). Any articles that differ in their conclusions would be analysed and discussed, and a final decision would be made by the third independent researcher (Guocan Yu).</p></sec><sec id="s2-9"><title>Data extraction</title><p>Basic study information and details of the nanopore sequencing diagnostic EPTB will be extracted from the screened included studies. Basic information will include year of publication, first author, patient selection methods, type of study, type of EPTB, adult or paediatric patients, presence of HIV, sample size, smear results (positive or negative) and reference standard (MTB culture or clinical diagnosis). Data relevant to the diagnosis of EPTB will include TP, FP, FN and TN values, sequencing methods (nanopore sequencing or next-generation sequencing), nanopore sequencing technology (such as MinION or GridION), sample type (such as cerebrospinal fluid, lymph node aspirates or core needle biopsy or tissue or pus, bone tissue, pericardial effusion or tissue, pleural tissue or effusion and urine) and whether or not targeted amplification was used for nanopore sequencing. As in the literature screening phase, the relevant information will again be extracted and validated against each other by two independent researchers. Any differences of opinion will be debated with a third independent researcher for final decision.</p></sec><sec id="s2-10"><title>Quality evaluation</title><p>We will use the Quality Assessment of Diagnostic Accuracy Studies<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> framework to evaluate the methodological rigour of the studies included in our analysis. This assessment will focus on key areas such as patient selection, metrics evaluation, adherence to reference standards and overall processes and timelines. Two researchers will independently conduct this evaluation, and to address any inconsistencies that may emerge, a third independent researcher will be consulted. Additionally, we will employ funnel plots to scrutinise the data for any potential missing studies.</p></sec><sec id="s2-11"><title>Data synthesis and statistical analysis</title><p>The study will incorporate the derivation of aggregated diagnostic performance indices, including pooled sensitivity (true-positive rate), specificity (true-negative rate), PPV/NPV, and AUC and their 95% CIs using TP, FP, FN and TN. These outcome metrics will be calculated and assessed separately according to different reference standards. The heterogeneity between studies will be assessed using the Q statistic, where p &gt; 0.1 means no heterogeneity and p &lt; 0.1 means heterogeneity. If there is significant heterogeneity, we will check the raw data of the included studies and explore the source of heterogeneity. If the number of studies is large enough, we will examine their sources and deal with heterogeneity through meta-regression and subgroup analysis. Subgroup analysis and meta-regression will consider differences in patient selection methods, type of study, type of EPTB, adult or paediatric patients, HIV status, smear results, sequencing methods, nanopore sequencing technology, sample type and whether or not targeted amplification. The robustness of the decisions made at each step and whether they will have an impact on the combined results will be assessed by sensitivity analysis. The statistical tool used will be Stata (V.15.0, Stata, College Station, TX, USA) with midas commands when the number of included studies is greater than or equal to four or RevMan (V.5.3 Cochrane Collaboration, Oxford, UK) when the number of included studies is less than four, and we will perform meta-analysis, generate forest plots and SROC curves.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> A p value of less than 0.05 will be considered statistically significant.</p></sec><sec id="s2-12"><title>Publication bias</title><p>Per the PRISMA-DTA Statement, assessing publication bias is not mandatory in diagnostic test accuracy meta-analyses, as existing evaluation methods remain inadequate for DTA studies.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p></sec><sec id="s2-13"><title>Evidence evaluation</title><p>We will categorise the quality of evidence into four levels: very low, low, moderate and high, based on the Grading of Recommendations Assessment, Development and Evaluation guidelines.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref></p></sec><sec id="s2-14"><title>Patient and public involvement</title><p>Patients and/or the public were not involved in this study.</p></sec><sec id="s2-15"><title>Ethics and dissemination</title><p>This investigation uses publicly accessible data repositories, exempting it from ethical review board approval requirements. On finalisation of the analysis, findings will be prepared for dissemination through submission to a reputable medical journal employing rigorous peer review processes. The study methodology adheres to established protocols for systematic review and meta-analysis.</p></sec></sec><sec sec-type="supplementary-material" id="s3"><title>Supplementary material</title><supplementary-material id="SP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2025-103676</object-id><label>online supplemental file 1</label><media xlink:href="bmjopen-15-9-s001.docx" id="d67e327" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SP2" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2025-103676</object-id><label>online supplemental file 2</label><media xlink:href="bmjopen-15-9-s002.docx" id="d67e332" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This project received support from the Hangzhou Biomedicine and Health Industry Development Supporting Science and Technology Special Project. YS, 2023WJC162; GY, 2023WJC312. The funder is not involved in study design, data gathering and analysis, publication decisions, or manuscript preparation.</p></fn><fn fn-type="other"><p>Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<ext-link xlink:href="https://doi.org/10.1136/bmjopen-2025-103676" ext-link-type="uri">https://doi.org/10.1136/bmjopen-2025-103676</ext-link>).</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Global tuberculosis report 2024</article-title><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><year>2024</year><comment>Available</comment><ext-link xlink:href="https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1</ext-link></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biakto</surname><given-names>KT</given-names></name><name name-style="western"><surname>Kusmawan</surname><given-names>IG</given-names></name><name name-style="western"><surname>Massi</surname><given-names>MN</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic accuracy of GeneXpert in the diagnosis of spinal tuberculosis: A systematic review and meta-analysis</article-title><source><italic toggle="yes">Narra J</italic></source><year>2024</year><volume>4</volume><elocation-id>e925</elocation-id><pub-id pub-id-type="doi">10.52225/narra.v4i2.925</pub-id><pub-id pub-id-type="pmid">39280292</pub-id><pub-id pub-id-type="pmcid">PMC11391995</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarro-Flores</surname><given-names>A</given-names></name><name name-style="western"><surname>Fernandez-Chinguel</surname><given-names>JE</given-names></name><name name-style="western"><surname>Pacheco-Barrios</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis</article-title><source>J Neurol</source><year>2022</year><volume>269</volume><fpage>3482</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1007/s00415-022-11052-8</pub-id><pub-id pub-id-type="pmid">35288778</pub-id><pub-id pub-id-type="pmcid">PMC8920747</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>N</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>BD</given-names></name><name name-style="western"><surname>Thwaites</surname><given-names>G</given-names></name></person-group><article-title>The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis</article-title><source>Tuberculosis (Edinb)</source><year>2010</year><volume>90</volume><fpage>361</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2010.08.005</pub-id><pub-id pub-id-type="pmid">20829117</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonard</surname><given-names>JM</given-names></name></person-group><article-title>Central Nervous System Tuberculosis</article-title><source>Microbiol Spectr</source><year>2017</year><volume>5</volume><pub-id pub-id-type="doi">10.1128/microbiolspec.tnmi7-0044-2017</pub-id><pub-id pub-id-type="pmcid">PMC11687486</pub-id><pub-id pub-id-type="pmid">28281443</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muneer</surname><given-names>A</given-names></name><name name-style="western"><surname>Macrae</surname><given-names>B</given-names></name><name name-style="western"><surname>Krishnamoorthy</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Urogenital tuberculosis - epidemiology, pathogenesis and clinical features</article-title><source>Nat Rev Urol</source><year>2019</year><volume>16</volume><fpage>573</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/s41585-019-0228-9</pub-id><pub-id pub-id-type="pmid">31548730</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>M</given-names></name><name name-style="western"><surname>Kon</surname><given-names>OM</given-names></name></person-group><article-title>Use of Xpert MTB/RIF and Xpert Ultra in extrapulmonary tuberculosis</article-title><source>Expert Rev Anti Infect Ther</source><year>2021</year><volume>19</volume><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1080/14787210.2020.1810565</pub-id><pub-id pub-id-type="pmid">32806986</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>G</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic accuracy of nanopore sequencing for the rapid diagnosis of pulmonary tuberculosis: A protocol for a systematic review and meta-analysis</article-title><source>PLoS One</source><year>2024</year><volume>19</volume><elocation-id>e0304162</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0304162</pub-id><pub-id pub-id-type="pmid">38843269</pub-id><pub-id pub-id-type="pmcid">PMC11156269</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mokaddas</surname><given-names>E</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name><name name-style="western"><surname>Eldeen</surname><given-names>H</given-names></name></person-group><article-title>Performance Comparison of GeneXpert MTB/RIF and ProbeTec ET Tests for Rapid Molecular Diagnosis of Extrapulmonary Tuberculosis in a Low TB/MDR-TB Incidence Country</article-title><source>Med Princ Pract</source><year>2021</year><volume>30</volume><fpage>277</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1159/000515254</pub-id><pub-id pub-id-type="pmid">33592621</pub-id><pub-id pub-id-type="pmcid">PMC8280443</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Nanopore sequencing technology and its applications</article-title><source><italic toggle="yes">MedComm</italic></source><year>2023</year><volume>4</volume><elocation-id>e316</elocation-id><pub-id pub-id-type="doi">10.1002/mco2.316</pub-id><pub-id pub-id-type="pmid">37441463</pub-id><pub-id pub-id-type="pmcid">PMC10333861</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Nanopore-based targeted next-generation sequencing of tissue samples for tuberculosis diagnosis</article-title><source>Front Microbiol</source><year>2024</year><volume>15</volume><elocation-id>1403619</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2024.1403619</pub-id><pub-id pub-id-type="pmid">39027106</pub-id><pub-id pub-id-type="pmcid">PMC11256091</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>G</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Targeted nanopore sequencing using clinical specimens for the rapid diagnosis of extrapulmonary tuberculosis</article-title><source>BMC Infect Dis</source><year>2024</year><volume>24</volume><elocation-id>710</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-024-09618-0</pub-id><pub-id pub-id-type="pmid">39030493</pub-id><pub-id pub-id-type="pmcid">PMC11264878</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement</article-title><source>Syst Rev</source><year>2015</year><volume>4</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/2046-4053-4-1</pub-id><pub-id pub-id-type="pmid">25554246</pub-id><pub-id pub-id-type="pmcid">PMC4320440</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McInnes</surname><given-names>MDF</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Thombs</surname><given-names>BD</given-names></name><etal>et al</etal></person-group><article-title>Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement</article-title><source>JAMA</source><year>2018</year><volume>319</volume><fpage>388</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.19163</pub-id><pub-id pub-id-type="pmid">29362800</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whiting</surname><given-names>PF</given-names></name><name name-style="western"><surname>Rutjes</surname><given-names>AWS</given-names></name><name name-style="western"><surname>Westwood</surname><given-names>ME</given-names></name><etal>et al</etal></person-group><article-title>QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies</article-title><source>Ann Intern Med</source><year>2011</year><volume>155</volume><fpage>529</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-155-8-201110180-00009</pub-id><pub-id pub-id-type="pmid">22007046</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L</given-names></name><name name-style="western"><surname>Ye</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Meta-analysis of diagnostic accuracy of nucleic acid amplification tests for abdominal tuberculosis</article-title><source>PLoS One</source><year>2023</year><volume>18</volume><elocation-id>e0289336</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0289336</pub-id><pub-id pub-id-type="pmid">38011098</pub-id><pub-id pub-id-type="pmcid">PMC10681219</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendoza</surname><given-names>C</given-names></name><name name-style="western"><surname>Kraemer</surname><given-names>P</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Clinical guidelines using the GRADE system (Grading of Recommendations Assessment, Development and Evaluation)</article-title><source>Rev Med Chil</source><year>2017</year><volume>145</volume><fpage>1463</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.4067/s0034-98872017001101463</pub-id><pub-id pub-id-type="pmid">29664529</pub-id></element-citation></ref></ref-list></back><sub-article id="sub-article1" article-type="aggregated-review-documents"><front-stub><title-group><article-title>Review Process File</article-title></title-group><pub-date pub-type="epub"><day>02</day><month>09</month><year>2025</year></pub-date></front-stub><body><fig id="d67e790" position="anchor" orientation="portrait"><media xlink:href="bmjopen-2025-103676.reviewer_comments.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>